ANEW MEDICAL, INC. (“ANEW” or the “Company”), a medical product development company (OTC:Pink: LEAS)), announced results presented at the European Society of Cell and Gene Therapy (ESCGT) from preclinical in vivo studies of its lead secreted-Klotho (s-KL) gene therapy candidate in a stringent animal model of human ALS. The SOD1G93A mouse model recapitulates most of ALS neuromuscular abnormalities, and it’s been shown that there are decreased mRNA levels of s-KL protein expressed in skeletal muscles, the motor cortex, and the lumbar spinal cord in these animals. Thus, long-term supplementation of the s-KL protein via gene therapy technology is an attract new measure for treatment of this deadly disease.

The technology was licensed on an exclusive worldwide basis from the Universitat Autonomo de Barcelona in Barcelona, Spain. ANEW’s lead gene therapy candidate utilizes a muscle-targeting AAV9 viral vector and a muscle tissue-specific promoter upstream of the s-KL gene to selectively express the s-KL protein in the muscles and nervous system of transgenic mice that overexpress the SOD1G93A gene, leading to the clinical signs and symptoms of ALS, also known as “Motor Neuron Disease” and “Lou Gehrig’s disease”. The overexpression of the SOD1 gene in humans is called “familial ALS” and occurs in 5%-10% of all ALS cases.

ALS is a progressive neurologic disorder characterized by the loss of cortical and spinal motor neurons, denervation of nerve endplates, axonal retraction and death to motor neurons resulting in muscle atrophy. Patients average 2-3 years of survival after initial diagnosis, so there is an urgent medical need for effective treatments of this deadly disease. The ALS neuropathology is mainly due to oxidative stress, neuroinflammation, excitotoxicity and mitochondrial dysfunction leading to loss of muscle mass, muscle endplate denervation, and ultimately death from respiratory failure.

Results show that the overexpression of the s-KL protein in muscles and CNS, mediated by the s-KL gene, a muscle-targeted AAV vector, and the muscle-specific promoter enhances motor function, yields higher number of innervated neuromuscular junctions, reduced oxidative stress and neuroinflammation, produces higher muscle action potential of major muscle groups, induces improved muscle strength and muscle mass, reduces glutamate-induced excitotoxicity in the spinal cord, delays the disease onset, and improves overall survival versus the non-treated control groups.

Dr. Joseph Sinkule, the Company’s CEO stated “our s-KL gene therapy construct exhibits robust and prolonged bioactivity in this model of ALS and these results support ALS as the first indication in clinical trials of this new approach to treat ALS. We look forward to expanding the testing of our lead candidate, ANEW-202, in the Profilin1 animal model of ALS that represents 90-95% of all human ALS cases called Sporadic ALS. The delivery and expression of the s-KL protein by the s-KL gene may be an effective therapy in this degenerative neuromuscular disease” said Dr. Sinkule. “The data open up additional avenues for the use of ANEW-202 in an expanding array of other neuromuscular and motor neuron diseases such as multiple sclerosis, muscular dystrophy, myasthenia gravis, and rare diseases like Lambert-Eaton disease, Friedreich’s ataxia, and spinal muscular atrophy. There may even be potential use in spinal cord injuries and peripheral nerve injuries but clearly, ALS is our lead indication.” says Dr. Sinkule.

ANEW MEDICAL, INC. (OTC:Pink: LEAS) is a technology and medical product development company focused on the development of therapeutics and diagnostics for a broad range of life-threating disease indications. ANEW underwent a reverse merger into a public shell (LEAS) in 2021 and still awaits FINRA’s approval of the broker/dealer name change to ANEW MEDICAL, INC. and a 2500-for-1 reverse stock split. The Company has offices in the US and in Spain. ANEW’s current portfolio consists of generic drugs that are in short supply in the US, biosimilar biologics targeting cancer and autoimmune diseases, and its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics. For more information on ANEW MEDICAL, INC. please visit

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding ANEW MEDICAL’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements because of various factors. ANEW MEDICAL assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in the Company’s annual reports filed with the SEC.

Leave a Reply

Your email address will not be published. Required fields are marked *